, Volume 2, Issue 3, pp 193–198 | Cite as

Effects of interleukin-2 (IL-2) on human plasma lipid, lipoprotein, and C-reactive protein

  • I. Bruce Rosenzweig
  • Donald A. Wiebe
  • Jacquelyn A. Hank
  • John J. Albers
  • Janet L. Adolphson
  • Ernest Borden
  • Earl S. Shrago
  • Paul M. Sondel


Six patients with confirmed malignant disease received four consecutive weekly cycles of human recombinant interleukin-2 (IL-2) 4 days/week, continuous iv. infusion, 3 × 106 U/m2/day. Plasma cholesterol decreased a mean of 7% within 24 hours after IL-2 infusion and decreased by 33% within 4 days. Plasma cholesterol was significantly lower than baseline concentration by day 21 (−21%), and day 25 (−41%) was significantly lower than day 21. Decreased plasma cholesterol was the result of decreased HDL and LDL cholesterol concentrations. Plasma triglyceride demonstrated a mean increase of 46% after 4 days of therapy and remained greater than baseline concentrations at all time points analyzed. Apolipoprotein AI and AII decreased concomitantly with HDL-cholesterol concentrations, whereas apolipoprotein B after an initial mean decrease of 17% during the first cycle was not significantly different from baseline during the fourth cycle. Apolipoprotein E and Lp(a) were not significantly affected by IL-2 treatment. Plasma C-reactive protein (CRP) increased by 79% within 24 hours of therapy, increased by 254% on day 4, then decreased to baseline concentrations by day 21 after 3 days off of IL-2. Day 25 CRP was elevated compared to both baseline and day 21 concentrations. IL-2 induced plasma lipoprotein changes may be due in part to the induction of interferon gamma.

Key words

apolipoproteins C-reactive protein interferon interleukin-2 



interleukin 2




low density lipoproteins

apo B

apolipoprotein B


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mule JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225: 1487–9.Google Scholar
  2. 2.
    Sondel PM, Hank JA, Kohler PC, Chen BP, Minkoff,DZ, Molenda JA. Destruction of autologous human lymphocytes by interleukin-2 activated cytotoxic cells. J. Immunol 1986; 137: 502–11.Google Scholar
  3. 3.
    Cheever MA, Thompson JA, Peace DJ. Potential uses of interleukin-2 in cancer therapy. Immunobiology 1986; 172: 365–82.Google Scholar
  4. 4.
    Greenberg PD, Cheever MA. Treatment of disseminated leukemia with cyclophosphamide and immune cells: Tumor immunity reflects long-term persistence of tumorspecific donor T Cells. J Immunol 1984; 133: 3401–7.Google Scholar
  5. 5.
    Palladino MA, Welte K, Carroll AM, Oettgen HF. Characterization of interleukin-2 (IL-2) -dependent cytotoxic T cell clones. V. Transfer of resistance to allografts and tumor grafts requires exogenous IL-2. Cell Immunol 1984; 86: 299–307.Google Scholar
  6. 6.
    Thompson JA, Peace DJ, Klarnet JP, Kern DE, Greenberg PD, Cheever MA. Eradication of disseminated murine leukemia by treatment with high dose interleukin-2. J Immunol 1986; 137: 3675–80.Google Scholar
  7. 7.
    Kohler PC, Hank JA, Exten R, Minkoff DZ, Wilson DG, Sondel PM. Clinical response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes. A case report and phase I trial. Cancer 1985; 55: 552–60.Google Scholar
  8. 8.
    Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: Responses, treatment related morbidity and histologic findings. JAMA 1986; 256: 3117–24.Google Scholar
  9. 9.
    Rosenberg SA, Lotze MT, Muel LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl. J Med 1987; 316: 889–97.Google Scholar
  10. 10.
    West WH, Taver KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898–905.Google Scholar
  11. 11.
    Moertel CG. On lymphokines, cytokines and breakthroughs (letter). JAMA 1986; 256: 3141.Google Scholar
  12. 12.
    Kohler PC, Hank JA, Moore KH, Storer B, Bechhofer R, Sondel PM. Phase I clinical evaluations of recombinant interleukin-2. In: Truitt RP, Gale RP, Bortin MM, eds. Cellular immunotherapy of cancer. New York: Alan R. Liss Publishing Company, 1987: 173–84.Google Scholar
  13. 13.
    Ehnholm C, Aho K, Huttunen JK, Kostiainen E, Mattila K, Pikkarainen J, Cantell K. Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases. Arteriosclerosis 1982; 2: 68–73.Google Scholar
  14. 14.
    Dixon RM, Borden EC, Keim NL, Anderson S, Spennetta TL, Tormey DC, Shrago E. Decreases in serum high-density-lipoprotein cholesterol and total cholesterol resulting from naturally produced and recombinant DNA-derived leukocyte interferons. Metabolism 1984; 33: 400–4.Google Scholar
  15. 15.
    Massaro ER, Borden EC, Hawkins MJ, Shrago E. Alterations in plasma lipoprotein composition resulting from recombinant alpha2 interferon. J Interferon Res 1986; 6: 655–62.Google Scholar
  16. 16.
    Hawkins M, Horning S, Kondrad M, Anderson S, Sielaff K, Rosno S, Schiesel J, Davis T, DeMets D, Merigan T, Borden E. Phase I evaluation of a synthetic mutant ofβ-interferon. Cancer Res 1985; 45: 5914–20.Google Scholar
  17. 17.
    Rosenzweig IB, Wiebe DA, Borden EC, Storer B, Shrago ES. Plasma lipoprotein changes induced byβ-interferon. Atherosclerosis 1987; 67: 261–7.Google Scholar
  18. 18.
    Borden EC, Rosenzweig IB, Byrne GI. Interferons: From virus inhibitor to modulator of amino acid and lipid metabolism. J Interferon Res 1987; 7: 591–6.Google Scholar
  19. 19.
    Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA.In vivo administration of purified human interleukin- 2. II Half life, immunologic effects and expansion of peripheral lymphoid cellsin vivo with recombinant IL-2. J Immunol 1985; 135: 2865–70.Google Scholar
  20. 20.
    Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470–3.Google Scholar
  21. 21.
    Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973; 19: 476–82.Google Scholar
  22. 22.
    Hatch FT, Lees RS. Practical methods for plasma lipoprotein. analysis. Adv Lipid Res 6: 1–68.Google Scholar
  23. 23.
    Rifai N, King ME. Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum. Clin Chem 1986; 32: 957–61.Google Scholar
  24. 24.
    Albers JJ, Adolphson JL, Hazzard WR. Radioimmunoassay of human plasma Lp(a) lipoprotein. J Lipid Res 1977; 18: 331–8.Google Scholar
  25. 25.
    Buitrago JMG, Cava F, Gomez del Campo A, Moyano JC, Navajo JA. Clinical evaluation of a fluorescence polarization immunoassay for quantifying C-reactive protein. Clin Chem 1988; 34: 595–6.Google Scholar
  26. 26.
    Snedecor GW, Cochran WG. Statistical methods. Ames: The Iowa State University Press, 1981.Google Scholar
  27. 27.
    Malmendier CL, Lontie JF, Sculier JP, Dubois DY. Modifications of plasma lipids, lipoproteins and apolipoproteins in advanced cancer patients treated with recombinant interleukin-2 and autologous lymphokine-activated killer cells. Atherosclerosis 1988; 73: 173–80.Google Scholar
  28. 28.
    Kurzrock R, Rohde MF, Quesada JR, Gianturco SH, Bradley WA, Sherwin SA, Gutterman JU. Recombinant γ interferon induces hypertriglyceridemia and inhibits postheparin lipase activity in cancer patients. J Exp Med 1986; 164: 1093–101.Google Scholar
  29. 29.
    Semb H, Peterson J, Tavernier J, Olivercrona T. Multiple effects of tumor necrosis factor on lipoprotein lipasein vivo. J Biol Chem 1987; 262: 8390–4.Google Scholar
  30. 30.
    Oppenheimer MJ, Oram JR, Bierman EL. Upregulation of high density lipoprotein receptor activity by γ-interferon associate with inhibition of cell proliferation. J Biol Chem 1988; 263: 19318–19323.Google Scholar
  31. 31.
    Friedland ML, Herbert PN. Lipoprotein abnormalities associated with a viral syndrome. JAMA 1982; 248: 82.Google Scholar
  32. 32.
    Alvarez C, Ramos A. Lipids, lipoproteins and apoproteins in serum during infection. Clin Chem 1986; 32: 142–5.Google Scholar
  33. 33.
    Dinarello CA. Induction of acute phase reactants by interleukin-1. In: Weissmann G, ed. Advances in inflammation research. New York: Raven Press, 1984: 203–25.Google Scholar
  34. 34.
    Sehgal PB, May LT, Tamm I, Vilcek J. Humanβ 2 interferon and B-cell differentiation factor BSF-2 are identical. Science 1987; 235: 731–2.Google Scholar
  35. 35.
    Garman RD, Jacobs KA, Clark SC, Raulet DH. B-cell-stimulatory factor 2β 2 interferon) functions as a second signal for interleukin 2 production by mature murine T cells. Proc Natl Acad Sci USA 1987; 84: 7629–33.Google Scholar
  36. 36.
    Baumann H, Onorato V, Gauldie J, Jahreis GP. Distinct sets of acute phase plasma proteins are stimulated by separate human hepatocyte-stimulating factors and monokines in rat hepatoma cells. J Biol Chem 1987; 262: 9756–68.Google Scholar
  37. 37.
    Gauldie J, Richards C, Harnish, D, Lansdorp P, Bauman H. Interferonβ 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987; 84: 7251–5.Google Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • I. Bruce Rosenzweig
    • 1
    • 2
  • Donald A. Wiebe
    • 1
    • 2
  • Jacquelyn A. Hank
    • 1
    • 2
  • John J. Albers
    • 1
    • 2
  • Janet L. Adolphson
    • 1
    • 2
  • Ernest Borden
    • 1
    • 2
  • Earl S. Shrago
    • 1
    • 2
  • Paul M. Sondel
    • 1
    • 2
  1. 1.Departments of Pathology and Laboratory Medicine, Pediatrics, Genetics, Human Oncology and Nutritional SciencesUniversity of WisconsinMadisonUSA
  2. 2.Departments of Medicine and PathologyUniversity of Washington and the Northwest Lipid Research ClinicSeattleUSA

Personalised recommendations